1. Home
  2. BTAI

as 09-18-2025 11:31am EST

$
-
.
-
-
+
$
-
.
-
-
+
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

Founded: 2017 Country:
United States
United States
Employees: N/A City: NEW HAVEN
Market Cap: 52.7M IPO Year: 2018
Target Price: $32.80 AVG Volume (30 days): 5.2M
Analyst Decision: Buy Number of Analysts: 5
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -11.08 EPS Growth: N/A
52 Week Low/High: $1.17 - $13.28 Next Earning Date: 11-13-2025
Revenue: $868,000 Revenue Growth: -63.88%
Revenue Growth (this year): -65.05% Revenue Growth (next year): 614.78%

BTAI Daily Stock ML Predictions

Share on Social Networks: